484671-60-5

Basic information

• Product Name: Benzoic acid (2S,3R,4S,6R)-4-dimethylamino-2-((E)-(3R,5R,6R,7R,9R,13S,14R)-14-ethyl-13-hydroxy-7-methoxy-3,5,7,9,11-pentamethyl-2,4,10-trioxo-13-vinyl-oxacyclotetradec-11-en-6-yloxy)-6-methyl-tetrahydro-pyran-3-yl ester
• Synonyms: Benzoic acid (2S,3R,4S,6R)-4-dimethylamino-2-((E)-(3R,5R,6R,7R,9R,13S,14R)-14-ethyl-13-hydroxy-7-methoxy-3,5,7,9,11-pentamethyl-2,4,10-trioxo-13-vinyl-oxacyclotetradec-11-en-6-yloxy)-6-methyl-tetrahydro-pyran-3-yl ester
• CAS NO: 484671-60-5
• Molecular Weight: 685.855
• Mol File: 484671-60-5.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: Benzoic acid (2S,3R,4S,6R)-4-dimethylamino-2-((E)-(3R,5R,6R,7R,9R,13S,14R)-14-ethyl-13-hydroxy-7-methoxy-3,5,7,9,11-pentamethyl-2,4,10-trioxo-13-vinyl-oxacyclotetradec-11-en-6-yloxy)-6-methyl-tetrahydro-pyran-3-yl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid (2S,3R,4S,6R)-4-dimethylamino-2-((E)-(3R,5R,6R,7R,9R,13S,14R)-14-ethyl-13-hydroxy-7-methoxy-3,5,7,9,11-pentamethyl-2,4,10-trioxo-13-vinyl-oxacyclotetradec-11-en-6-yloxy)-6-methyl-tetrahydro-pyran-3-yl ester(484671-60-5)
• EPA Substance Registry System: Benzoic acid (2S,3R,4S,6R)-4-dimethylamino-2-((E)-(3R,5R,6R,7R,9R,13S,14R)-14-ethyl-13-hydroxy-7-methoxy-3,5,7,9,11-pentamethyl-2,4,10-trioxo-13-vinyl-oxacyclotetradec-11-en-6-yloxy)-6-methyl-tetrahydro-pyran-3-yl ester(484671-60-5)

Safety Data

• Hazardous Substances Data: 484671-60-5(Hazardous Substances Data)

Upstream product

• 484671-59-2 Benzoic acid (2S,3R,4S,6R)-4-dimethylamino-2-((E)-(3R,5R,6R,7R,9R,13S,14R)-14-ethyl-13-formyl-13-hydroxy-7-methoxy-3,5,7,9,11-pentamethyl-2,4,10-trioxo-oxacyclotetradec-11-en-6-yloxy)-6-methyl-tetrahydro-pyran-3-yl ester 
• 1779-49-3 Methyltriphenylphosphonium bromide 
• 484670-64-6 clarithromycin dibenzoate 
• 93-97-0 benzoic acid anhydride 
• 81103-11-9 clarithromycin 
• 484671-56-9 C₅₅H₈₁NO₁₉S 
• 484671-55-8 C₅₄H₇₉NO₁₇ 
• 484671-54-7 C₅₄H₈₁NO₁₇ 
• 484671-57-0 C₅₄H₇₇NO₁₆ 
• 484671-53-6 C₅₂H₇₉NO₁₆ 
• 484670-63-5 C₅₅H₈₃NO₁₅ 
• 484670-61-3 C₅₂H₇₉NO₁₅ 
• 484670-65-7 C₅₂H₇₇NO₁₄ 
• 484671-58-1 Benzoic acid (2S,3R,4S,6R)-4-dimethylamino-2-((E)-(3R,4S,5S,6R,7R,9R,13R,14R)-14-ethyl-4,13-dihydroxy-13-hydroxymethyl-7-methoxy-3,5,7,9,11-pentamethyl-2,10-dioxo-oxacyclotetradec-11-en-6-yloxy)-6-methyl-tetrahydro-pyran-3-yl ester 

Downstream Products

• 484673-82-7 C₅₁H₆₉N₅O₁₁ 

Relevant articles and documents

Synthesis and antibacterial activity of novel C12 vinyl ketolides

A novel series of C12 vinyl erythromycin derivatives have been discovered which exhibit in vitro and in vivo potency against key respiratory pathogens. The C12 modification involves replacing the natural C 12 methyl group in the erythromycin core with a vinyl group via chemical synthesis. From the C12 vinyl macrolide core, a series of C12 vinyl ketolides was prepared. Several compounds were found to be potent against macrolide-sensitive and -resistant bacteria. The C12 vinyl ketolides 6j and 6k showed a similar antimicrobial spectrum and comparable activity to the commercial ketolide telithromycin. However, the pharmacokinetic profiles of C12 vinyl ketolides 6j and 6k in rats differ from that of telithromycin by having higher lung-to-plasma ratios, larger volumes of distribution, and longer half-lives. These pharmacokinetic differences have a pharmacodynamic effect as both 6j and 6k exhibited better in vivo efficacy than telithromycin in rat lung infection models against Streptococcus pneumoniae and Haemophilus influenzae.